The International Prognostic Scoring System (IPSS) is based on the:1
Based on these factors, patients are stratified into 1 of 4 risk groups (Low, Int-1, Int-2, and High) that have distinct survival rates (Table).1
|Bone marrow blasts (%)||< 5||5-10||—||11-20||21-30|
|Cytopenias†, n||0 or 1||2 or 3||—||—||—|
|Score||IPSS subgroup||Median survival (years)|
*Good: normal, -Y, del(5q), del(20q); intermediate: other abnormalities; poor: complex (≥ 3 abnormalities) or chromosome 7 anomalies.
†Platelets < 100,000/μL; hemoglobin < 10 g/dL; neutrophils < 1,800/μL.
Reproduced from Greenberg P, et al. Blood. 1997;89:2079-88 © 1997 by The American Society of Hematology.
The IPSS scoring system is used only at the time of MDS diagnosis as it does not take into account the impact of transfusions on the prognosis of MDS patients.Learn about a dynamic risk stratification system >
All fields are required.
You are now leaving the IronHealthalliance.com website by opening an external website independently operated and not managed by Novartis. Novartis assumes no responsibility for the site you are about to visit. If you do not wish to leave this site, click "Cancel." Otherwise, click "Continue".